FAPESP, GSK and Biominas will support health research Versão em português
FAPESP, GlaxoSmithKline Brasil (GSK) and Biominas announce a call for proposals to support innovative preclinical research focusing on respiratory diseases, immuno-inflammation, immuno-oncology, and HIV carried out by researchers affiliated to small and medium sized businesses in the State of São Paulo.
FAPESP will support projects according to the rules and regulations of its Innovative Research in Small Business Program (PIPE). GSK and Biominas may offer scientific, technical and business support and advice.
There is no restriction on the target market, but the companies must have less than five full time employees.
A maximum of ten projects will be selected. Each proposal will be eligible for support for a period of up to nine months and up to R$200,000 in funding (Phase 1). A maximum of three of these projects will be eligible for further support, PIPE Phase 2, for a period of up to two years each (after the end of such initial period) and up to R$1,000,000 in funding.
FAPESP will receive proposals until August 14, 2020 – or before, if the maximum number of proposals is reached.
The call for proposals is available at www.fapesp.br/en/11940.